A comprehensive appraisal of dabigatran etexilate clinical evidence and applications: A 10-year-long story

Giulio Francesco Romiti, Bernadette Corica, Marco Proietti

Research output: Contribution to journalArticlepeer-review

Abstract

During the last decade, non-vitamin K antagonist oral anticoagulants (NOACs) revolutionized the thromboprophylaxis management of several medical conditions, including atrial fibrillation and venous thromboembolism. Dabigatran etexilate was the first NOAC widely available worldwide, and it is currently the only one that directly inhibits thrombin. More recently, the availability of idarucizumab, a specific reversal agent, has increased the safety of dabigatran use in clinical practice, especially for those patients with severe and life-threatening bleeding. This review aims to summarize current evidence on dabigatran, starting from its pharmacological characteristics, and providing an updated overview of pivotal randomized controlled trials and real-world data on its efficacy and safety.

Original languageEnglish
Pages (from-to)215-226
Number of pages12
JournalFuture Cardiology
Volume17
Issue number2
DOIs
Publication statusPublished - Mar 2021

Keywords

  • atrial fibrillation
  • dabigatran
  • non-vitamin K antagonist oral anticoagulants
  • oral anticoagulant drugs
  • thromboembolic risk

ASJC Scopus subject areas

  • Molecular Medicine
  • Cardiology and Cardiovascular Medicine

Fingerprint Dive into the research topics of 'A comprehensive appraisal of dabigatran etexilate clinical evidence and applications: A 10-year-long story'. Together they form a unique fingerprint.

Cite this